Skip to content

    Pfizer

    PFIZERGood
    Healthcare·5 Aug 2020
    Management Summary

    Pfizer India delivered a resilient performance in Q1 FY21 despite significant COVID-19 headwinds. While the hospital and pediatric vaccine segments were severely impacted by lockdowns, the core Internal Medicine portfolio grew strongly following a successful sales model restructuring. Exceptional cost control and tax benefits led to double-digit profit growth despite a revenue contraction.

    Highlights

    7

    • Revenue from operations stood at ₹515 crores, a decline of 5.3% YoY due to COVID-19 impact on hospital and vaccine segments.

    • Net Profit (PAT) grew by 10% YoY to ₹124 crores, supported by a lower effective tax rate of 25% vs 30% last year.

    • EBITDA margin expanded significantly to 37% from 31% YoY, primarily driven by a sharp reduction in travel and promotional expenses.

    • Internal Medicine business (55% of revenue) logged healthy growth of 13% following a major go-to-market restructuring in Q4 FY20.

    • Hospital (Critical Care) business declined by 41% as ICU wards were prioritized for COVID patients and elective surgeries were postponed.

    • Vaccine business declined by 23% as pediatric clinics remained closed during the lockdown, though adult vaccination showed resilience.

    • The company declared and paid a special Platinum Jubilee dividend of ₹320 per equity share in May 2020.

    Concerns

    1

    • Prolonged impact on Hospital/Critical Care segment

    Key financials

    Single quarter

    05 metrics
    1. 01Revenue from Operations₹515 Cr-5.3%YoY
    2. 02EBITDA Margin37%
    3. 03Profit from Operations₹159 Cr+13%YoY
    4. 04PAT₹124 Cr+10%YoY
    5. 05Other Income₹17 Cr-52.8%YoY

    Segment breakdown

    Internal Medicine
    13% Revenue Growth55% Revenue Share
    Hospital (Critical Care)
    -41% Revenue Growth
    Vaccines
    -23% Revenue Growth
    Consumer Healthcare
    -27% Revenue Growth
    List

    Guidance & targets

    4
    CategoryTargetPriority
    Margin
    EBITDA Margin Band
    25% to 30%
    		Medium
    Revenue
    Minipress XL Annualized Sales
    ₹70-80 crores
    		High
    Revenue
    Nexium Sales Growth
    ₹40 crores
    		Medium
    Revenue
    Meronem Annual Sales Ambition
    ₹100 crores
    		Medium

    Risks & concerns

    5
    RiskSeverity

    Prolonged impact on Hospital/Critical Care segment

    ICUs remain full with COVID patients, leaving little room for elective surgeries and transplants that drive antibiotic sales. — Management acknowledged

    high

    Normalization of EBITDA margins

    Current 37% margins are unsustainable as travel and promotional activities resume. — Management acknowledged

    medium

    Divestment of Consumer and Upjohn portfolios

    These portfolios (contributing ~4% of sales) will be divested at some point, leading to a small revenue leak. — Management acknowledged

    low

    Areas of Evasion(2)

    • Specific details on the COVID vaccine's commercial path in India.
    • Specific therapeutic segments for the 5-year new product pipeline.

    Q&A highlights

    3

    “I welcome the competition... I believe the market will expand and everyone will have a share of the pie. We are still going to be the only 13 valent in the country.”

    Investors were concerned about Serum Institute's entry into the private market; management believes low penetration allows for multiple players.

    asked by Gagan Thareja

    2 min read5 chapters

    Detailed Narrative

    01

    Segmental Divergence Under COVID-19

    The quarter was defined by a sharp split in performance. The Internal Medicine segment, which includes legacy brands like Becosules and Corex, grew 13% YoY. In contrast, the Hospital business plummeted 41% as ICU wards were dedicated to COVID-19 patients, halting elective surgeries. Vaccines also saw a 23% decline as pediatric footfalls vanished during the lockdown. Management estimated the net revenue impact of COVID-19 at approximately ₹57 crores for the quarter.

    02

    Strategic Restructuring of Internal Medicine

    In Q4 FY20, Pfizer executed a major restructuring of its Internal Medicine business (55% of revenue). The new model uses a mix of 100% Pfizer FTEs in select territories and a 100% contract sales model in others. This 'feet on the ground' approach allowed the company to clock 100% of its budget during the peak COVID months of April-June, signaling a successful turnaround for this previously 'see-saw' business.

    03

    Margin Expansion and Sustainability

    EBITDA margins reached an exceptional 37% in Q1, up from 31% YoY. This was largely due to 'other expenses' falling to 13% of sales (₹65 crores) from 19% (₹100 crores) as travel and physical doctor conferences were replaced by digital engagement. CFO Milind Patil cautioned that while some digital efficiencies will remain, margins are expected to normalize to the 25-30% range as competitive intensity and field activities return.

    04

    Innovative Portfolio and Pipeline

    Pfizer continues to shift toward its global innovative portfolio, which now accounts for 48.6% of sales compared to 36.3% in 2016. New products launched in FY20 contributed ₹170 crores (8% of sales). Zavicefta, launched last year, reached ₹32-33 crores in sales. Management remains focused on maximizing the global Pfizer portfolio in India, though they were tight-lipped about specific upcoming launch dates.

    05

    Vaccine Dynamics and Competition

    While pediatric Prevenar sales fell 25% in Q1, adult vaccination (₹11 crores in Q1) is viewed as a major future growth driver due to increased health awareness. Addressing the entry of Serum Institute's pneumococcal vaccine, management expressed confidence in Prevenar's 20-year efficacy record and 13-valent differentiation, believing the new competition will primarily serve to expand a currently under-penetrated market.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.